Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Etoposide and Carboplatin in Extensive Stage Small Cell Lung Cancer (SCLC)
Study Number: 

PH 278815

Phase: 
Early Phase
Trial categories: 
Small Cell Lung Cancer (SCLC)
Lung
Principal Investigator: